FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutical industry, namely to methods of increasing lymphocyte count. Method of increasing the lymphocyte count in a subject in need thereof, comprising administering to the subject an interleukin-7 (IL-7) hybrid protein comprising a first domain, a second domain and a third domain, where (a) the first domain includes an IL-7 protein which is capable of binding to the IL-7 receptor, (b) the second domain contains an oligopeptide containing from 1 to 10 amino acid residues; and (c) third domain comprises a fragment which prolongs the half-life of the IL-7 fusion protein, wherein said method is characterized by that from 600 mcg/kg to 2000 mcg/kg of this fusion protein IL-7 is administered every 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 80 days, 90 days or 100 days. Method of increasing the lymphocyte count in a subject in need thereof, comprising administering to the subject interleukin-7 (IL-7) fusion protein, wherein the IL-7 fusion protein comprises: (a) a set of amino acid sequences presented in any of SEQ ID NO: 15 to 20, and (b) a fragment which prolongs the half-life of the IL-7 fusion protein, and wherein said method is characterized by that from 600 mcg/kg to 2000 mcg/kg of this IL-7 fusion protein is administered every 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 80 days , 90 days or 100 days. Use of interleukin-7 (IL-7) fusion protein to increase the number of lymphocytes in a subject in need thereof, wherein the IL-7 fusion protein comprises a first domain, a second domain and a third domain, wherein (a) the first domain comprises an IL-7 protein which is capable of binding to the IL-7 receptor, (b) the second domain contains an oligopeptide containing from 1 to 10 amino acid residues; and (c) third domain comprises a fragment which prolongs the half-life of the IL-7 fusion protein, where from 600 mcg/kg to 2000 mcg/kg of the IL-7 fusion protein is administered every 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 80 days, 90 days or 100 days. Use of interleukin-7 (IL-7) fusion protein in the preparation of a drug for increasing the number of lymphocytes in a subject in need thereof, where from 600 mcg/kg to 2000 mcg/kg of this IL-7 fusion protein is suitable for administration to subject every 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 80 days, 90 days or 100 days, and wherein the IL-7 fusion protein comprises a first domain, a second domain and third domain, where (a) the first domain comprises an IL-7 protein which is capable of binding to the IL-7 receptor, (b) the second domain contains an oligopeptide containing from 1 to 10 amino acid residues; and (c) the third domain contains a fragment which prolongs the half-life of the fusion protein IL-7. Use of a pharmaceutical composition containing as an active ingredient a hybrid protein of interleukin-7 (IL-7) containing a first domain, a second domain and a third domain, where: (a) a first domain comprises an IL-7 protein which is capable of binding to an IL-7 receptor; (b) the second domain contains an oligopeptide containing from 1 to 10 amino acid residues; and (c) a third domain comprises a fragment which prolongs the half-life of the IL-7 fusion protein, for administering to subject from 600 mcg/kg to 2000 mcg/kg of this IL-7 fusion protein every 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 80 days, 90 days or 100 days, and where the subject needs an increase in the lymphocyte count.
EFFECT: use of the group of inventions provides an increase in the number of lymphocytes in a subject in need thereof, use in the manufacture of a medicinal agent.
43 cl, 15 dwg, 6 tbl, 2 ex
